Literature DB >> 27663637

Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors.

Marjorie Poggi1, Matthias Canault1, Marie Favier1,2, Ernest Turro3,4, Paul Saultier1, Dorsaf Ghalloussi1, Veronique Baccini1, Lea Vidal1, Anna Mezzapesa1, Nadjim Chelghoum5, Badreddine Mohand-Oumoussa5, Céline Falaise6, Rémi Favier7, Willem H Ouwehand3,8, Mathieu Fiore6,9, Franck Peiretti1, Pierre Emmanuel Morange1,6, Noémie Saut1,6, Denis Bernot1, Andreas Greinacher10, Nihr BioResource11, Alan T Nurden12, Paquita Nurden6,12, Kathleen Freson13, David-Alexandre Trégouët14,15,16, Hana Raslova2, Marie-Christine Alessi17,6.   

Abstract

Variants in ETV6, which encodes a transcription repressor of the E26 transformation-specific family, have recently been reported to be responsible for inherited thrombocytopenia and hematologic malignancy. We sequenced the DNA from cases with unexplained dominant thrombocytopenia and identified six likely pathogenic variants in ETV6, of which five are novel. We observed low repressive activity of all tested ETV6 variants, and variants located in the E26 transformation-specific binding domain (encoding p.A377T, p.Y401N) led to reduced binding to corepressors. We also observed a large expansion of megakaryocyte colony-forming units derived from variant carriers and reduced proplatelet formation with abnormal cytoskeletal organization. The defect in proplatelet formation was also observed in control CD34+ cell-derived megakaryocytes transduced with lentiviral particles encoding mutant ETV6. Reduced expression levels of key regulators of the actin cytoskeleton CDC42 and RHOA were measured. Moreover, changes in the actin structures are typically accompanied by a rounder platelet shape with a highly heterogeneous size, decreased platelet arachidonic response, and spreading and retarded clot retraction in ETV6 deficient platelets. Elevated numbers of circulating CD34+ cells were found in p.P214L and p.Y401N carriers, and two patients from different families suffered from refractory anemia with excess blasts, while one patient from a third family was successfully treated for acute myeloid leukemia. Overall, our study provides novel insights into the role of ETV6 as a driver of cytoskeletal regulatory gene expression during platelet production, and the impact of variants resulting in platelets with altered size, shape and function and potentially also in changes in circulating progenitor levels. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27663637      PMCID: PMC5286936          DOI: 10.3324/haematol.2016.147694

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  41 in total

1.  TEL is a sequence-specific transcriptional repressor.

Authors:  R G Lopez; C Carron; C Oury; P Gardellin; O Bernard; J Ghysdael
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

2.  Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.

Authors:  Anna Dolnik; Julia C Engelmann; Maren Scharfenberger-Schmeer; Julian Mauch; Sabine Kelkenberg-Schade; Berit Haldemann; Tamara Fries; Jan Krönke; Michael W M Kühn; Peter Paschka; Sabine Kayser; Stephan Wolf; Verena I Gaidzik; Richard F Schlenk; Frank G Rücker; Hartmut Döhner; Claudio Lottaz; Konstanze Döhner; Lars Bullinger
Journal:  Blood       Date:  2012-09-13       Impact factor: 22.113

3.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

4.  DNA binding by the ETS protein TEL (ETV6) is regulated by autoinhibition and self-association.

Authors:  Sean M Green; H Jerome Coyne; Lawrence P McIntosh; Barbara J Graves
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

5.  A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and chromosome 11 deletion at 11q23.

Authors:  J Breton-Gorius; R Favier; J Guichard; D Cherif; R Berger; N Debili; W Vainchenker; L Douay
Journal:  Blood       Date:  1995-04-01       Impact factor: 22.113

6.  Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42.

Authors:  Irina Pleines; Sebastian Dütting; Deya Cherpokova; Anita Eckly; Imke Meyer; Martina Morowski; Georg Krohne; Harald Schulze; Christian Gachet; Najet Debili; Cord Brakebusch; Bernhard Nieswandt
Journal:  Blood       Date:  2013-07-16       Impact factor: 22.113

Review 7.  Rho GTPases in platelet function.

Authors:  J E Aslan; O J T McCarty
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

Review 8.  The critical role of chromosome translocations in human leukemias.

Authors:  J D Rowley
Journal:  Annu Rev Genet       Date:  1998       Impact factor: 16.830

9.  Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.

Authors:  Sabine Topka; Joseph Vijai; Michael F Walsh; Lauren Jacobs; Ann Maria; Danylo Villano; Pragna Gaddam; Gang Wu; Rose B McGee; Emily Quinn; Hiroto Inaba; Christine Hartford; Ching-Hon Pui; Alberto Pappo; Michael Edmonson; Michael Y Zhang; Polina Stepensky; Peter Steinherz; Kasmintan Schrader; Anne Lincoln; James Bussel; Steve M Lipkin; Yehuda Goldgur; Mira Harit; Zsofia K Stadler; Charles Mullighan; Michael Weintraub; Akiko Shimamura; Jinghui Zhang; James R Downing; Kim E Nichols; Kenneth Offit
Journal:  PLoS Genet       Date:  2015-06-23       Impact factor: 5.917

10.  Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia.

Authors:  Federica Melazzini; Flavia Palombo; Alessandra Balduini; Daniela De Rocco; Caterina Marconi; Patrizia Noris; Chiara Gnan; Tommaso Pippucci; Valeria Bozzi; Michela Faleschini; Serena Barozzi; Michael Doubek; Christian A Di Buduo; Katerina Stano Kozubik; Lenka Radova; Giuseppe Loffredo; Sarka Pospisilova; Caterina Alfano; Marco Seri; Carlo L Balduini; Alessandro Pecci; Anna Savoia
Journal:  Haematologica       Date:  2016-06-30       Impact factor: 9.941

View more
  24 in total

Review 1.  ETV6 in hematopoiesis and leukemia predisposition.

Authors:  Hanno Hock; Akiko Shimamura
Journal:  Semin Hematol       Date:  2017-04-07       Impact factor: 3.851

2.  Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity.

Authors:  Praveen K Suraneni; Seth J Corey; Michael J Hession; Rameez Ishaq; Arinola Awomolo; Shirin Hasan; Chirag Shah; Hui Liu; Amittha Wickrema; Najet Debili; John D Crispino; Elizabeth A Eklund; Yolande Chen
Journal:  Blood Adv       Date:  2018-12-11

Review 3.  Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia.

Authors:  Yoshihiro Gocho; Jun J Yang
Journal:  Blood       Date:  2019-07-16       Impact factor: 22.113

Review 4.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

5.  Predisposition to childhood acute lymphoblastic leukemia caused by a constitutional translocation disrupting ETV6.

Authors:  Tekla Järviaho; Benedicte Bang; Vasilios Zachariadis; Fulya Taylan; Jukka Moilanen; Merja Möttönen; C I Edvard Smith; Arja Harila-Saari; Riitta Niinimäki; Ann Nordgren
Journal:  Blood Adv       Date:  2019-09-24

Review 6.  Germline ETV6 mutations and predisposition to hematological malignancies.

Authors:  Simone Feurstein; Lucy A Godley
Journal:  Int J Hematol       Date:  2017-05-29       Impact factor: 2.490

Review 7.  Genetic predisposition to hematologic malignancies: management and surveillance.

Authors:  Lucy A Godley; Akiko Shimamura
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

8.  ETV6-related thrombocytopenia and leukemia predisposition.

Authors:  Jorge Di Paola; Christopher C Porter
Journal:  Blood       Date:  2019-06-27       Impact factor: 22.113

Review 9.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

Review 10.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.